title: Danazol and the premenstrual syndrome.
abstract: Danazol as a powerful antigonadotrophin is a logical mode of treatment for patients with premenstrual symptoms. Its preliminary use in a dose 200-800 mg daily is reported. Two groups of patients were treated and of 12 patients with severe symptoms (Group I) six benefited from treatment. The second group (Group II) presenting as fresh cases were given 400 mg daily as the first or second choice of treatment. This group had a high drop out rate and any benefit from treatment was marred by the side effects. Danazol will continue to be used where the symptoms are resistant to other treatment, especially when breast tenderness is predominant. The dose should be the minimum required for relief of symptoms.
mesh_terms: D002986:Clinical Trials as Topic; D003613:Danazol / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D011245:Pregnadienes / Q000627:therapeutic use*; D011293:Premenstrual Syndrome / Q000188:drug therapy*
chemical_list: D011245:Pregnadienes; D003613:Danazol